ASCO 2022 | ARCHES: radiographic progression in the absence of PSA progression in patients with mHSPC

Andrew J. Armstrong, MD, Duke Cancer Center, Durham, NC, presents the findings of a post hoc analysis of ARCHES (NCT02677896), a Phase III study which demonstrated that enzalutamide and androgen deprivation therapy (ADT) significantly reduced the risk of radiographic progression and increased overall survival in men with metastatic hormon-sensitive prostate cancer (mHSPC), regardless of baseline PSA levels. This lead to the FDA approval of enzalutamide plus ADT in this patient population. In this post hoc analysis of ARCHES, Dr Armstrong reports frequent discordance between radiographic progression and PSA progression, therefore regular imaging is recommended to detect radiographic progression among patients treated with potent androgen receptor pathway inhibitor as serial PSA monitoring alone may not be sufficient to detect radiographic progression in many patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.